WO2001057203A1 - NOUVEAU GENE TIG104α ET PROTEINE TIG104α CODEE PAR CE GENE - Google Patents

NOUVEAU GENE TIG104α ET PROTEINE TIG104α CODEE PAR CE GENE Download PDF

Info

Publication number
WO2001057203A1
WO2001057203A1 PCT/JP2001/000689 JP0100689W WO0157203A1 WO 2001057203 A1 WO2001057203 A1 WO 2001057203A1 JP 0100689 W JP0100689 W JP 0100689W WO 0157203 A1 WO0157203 A1 WO 0157203A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
human
gene
tig104α
seq
Prior art date
Application number
PCT/JP2001/000689
Other languages
English (en)
Japanese (ja)
Inventor
Tetsu Akiyama
Osamu Higuchi
Hiroko Ide
Original Assignee
Taisho Pharmaceutical Co.,Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co.,Ltd. filed Critical Taisho Pharmaceutical Co.,Ltd.
Priority to AU2001230560A priority Critical patent/AU2001230560A1/en
Publication of WO2001057203A1 publication Critical patent/WO2001057203A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Definitions

  • the present invention relates to a novel protein TIG 104 that controls an intracellular proteolytic reaction (proteasome-based proteolytic reaction) by a proteasome, and a gene tig 104 ⁇ that encodes the protein.
  • TGF Transform growth factor, TGF-31-5, consisting of activin that is important for mesoderm induction, BMP that promotes bone formation, and so on. It is not only involved in embryonic morphogenesis, but also closely related to diseases such as cirrhosis, glomerulonephritis, pulmonary fibrosis and other fibrotic diseases and cancers, as well as diseases in all areas such as orthopedics and ophthalmology. ing.
  • TGF- / 31 When TGF- / 31 binds to the TGF-i31 receptor, which is located on the target cell, the signal is transmitted to a transcription factor called Smad via the serine / threonine kinase activity of Recept Yuichi. You. Phosphorylated Smads rapidly translocate into the nucleus, bind to the transcriptional regulatory region of the target gene, and promote gene expression. This series of intracellular signaling mechanisms is commonly used in all molecules of the TGF-3 family. Disclosure of the invention
  • TGF-1 The physiological role of TGF-1 is that after the signal that the molecule has acted on the corresponding receptor has been transmitted to the Iffl vesicle, various genes respond and the unknown living liver is expressed. It is thought to be exerted. It is presumed that if such an organism could be identified, it would be possible to use the organism liver directly as a medicine or indirectly search for a drug compound.
  • proteasome protein reaction control factor comprising an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence of SEQ ID NO: 1;
  • Protein 1 and 104 are composed of 355 amino acids, have an estimated liver volume of about 41.6 kDa, an apparent ⁇ amount on SDS-PAGE of about 42 kDa, and have an isoelectric point of 9.68. It is a rich cellular protein. An amino acid sequence that is considered to be a nuclear translocation signal was observed in the amino terminal region, and the presence of the protein in the cell nucleus was confirmed by a test using an antibody.
  • F-box a functional domain found in the terminal region of lipoxyl. Proteins having an F-box domain can bind to Skp 1 and Fk via the F-box domain.
  • the SCF complex is another term for the E3-ubiquitinase complex and plays an important role in substrate-specific proteolysis by proteasomes.
  • the protein T IG104 ⁇ also interacts with the S k ⁇ 1 protein and controls the degradation of c-Myc molecule, one of the proteasome targets. Therefore, the protein TIG104 ⁇ was presumed to be a protein that controls proteolytic reactions in ubiquitination and proteolytic proteolysis.
  • TIG104 ⁇ is considered to have a function as a tumor suppressor by promoting ⁇ of the c-Myc protein and acting in a suppressive manner on cell proliferation.
  • FIG. 1 shows the results of forced expression of the recombinant human gene TIG104 ⁇ in human cell line 293 T cells.
  • FIG. 2 shows the results of an interaction experiment between human TIG104 ⁇ protein and human Sk ⁇ 1 protein.
  • FIG. 3 shows the results of a co-precipitation experiment of human TIG104 ⁇ protein and human Myc protein in human cell line 293 ⁇ cells.
  • FIG. 4 shows the amino acid sequence of TIG104. BEST MODE FOR CARRYING OUT THE INVENTION Gene !; i gl 04o! Is represented by SEQ ID NO: 2
  • a recombinant gene can be prepared by a general gene recombination technique using an appropriate host vector system.
  • Suitable vectors include E. coli-derived plasmids (eg, BR322, pUCl18, etc.), Bacillus subtilis-derived plasmids (eg, UB110, 1 (194, etc.), yeast-derived plasmids (eg, pSH19, etc.),
  • animal viruses such as bacteriophage retrovirus and vaccinia virus can be used, etc.
  • a translation initiation codon and a translation termination codon can be deleted using an appropriate synthetic DNA adapter.
  • an appropriate expression promoter is connected upstream of the gene, and the promoter to be used may be appropriately selected depending on the host, for example, when the host is Escherichia coli. , T7 promoter, lac promoter overnight, trp promoter, ⁇ -PL promoter, etc.
  • the host is Bacillus sp. If the host is yeast, the PHO5 promoter, GAP promoter, ADH promoter, etc., and if the host is animal cells, the SV40-derived promoter, retrovirus promoter, etc.
  • the gene can also be expressed as a fusion protein with another protein (eg, daltathione S-transferase, protein A, etc.). Suitable Proteases
  • Hosts that can be used for expression of the gene tig 104a include various strains of Escherichia iaco 1 i, a bacterium belonging to the genus Escherichia, various difficulties of Bacill 1 1 uss ub ti 1 is, a bacterium belonging to the genus Bacillus, and yeast.
  • S acchar omy ces As S acchar omy ces
  • a conventional method or a transformation method generally used for each host cell can be applied.
  • SEQ ID NO: 2 SEQ ID No. 2
  • a functional element that hybridizes with the DNA and controls a proteasomal protein Is also within the scope of the invention.
  • the degree of the above DNA mutation is within an allowable range as long as it has a homology of 80% or more with the DNA sequence of the ti gl04 ⁇ ;
  • the degree of hybridization of the S ⁇ tig 104 is as follows under normal conditions (for example, when the probe is labeled with the DIG DNA Labeling kit (Cat No. 1175033 manufactured by Boehringer Mannheim)). Hybridized in DIG Easy Hy b solution (Boehringer Mannheim Cat. No. 1603558) at 50 ° C and in a 0.5 XSSC solution (containing 0.1% [w / v] SDS) at 50 ° C. In a Southern hybridization under conditions that wash the membrane (1XSSC ⁇ 0.15M NaCl, 0.015M sodium citrate) It only needs to hybridize to i gl 04 «.
  • a protein encoded by a mutant gene having high homology to the gene tgl04 ⁇ , which controls a proteasome-based proteolytic reaction is also included in the scope of the present invention.
  • the mutant are within the scope of the present invention.
  • the side chains of the amino acids that are the constituents of the protein are different in their properties, charge, size, etc., but do not substantially affect the three-dimensional structure (also called three-dimensional structure) of the whole protein Some conservative relationships in the sense of this are known empirically and by physics.
  • glycine (Gly) and proly (Pro) Gly and alanine (Al a) or palin (Val), leucine (Leu) and isoleucine (I 1 e), glutamic acid (Glu) and glutamine (Gin), asparaginic acid (As ) And asparagine (Asn), cysteine (Cys) and threonine (T hr), Thr and serine (Ser) or A1a, lysine (Lys) and arginine (Ar g), and the like.
  • the mutation is the same as that of protein TIG104. If the mutation is highly conserved in the dimensional structure and the mutant protein is a factor that controls the proteasome-based protein ⁇ reaction like TIG104, these can be said to be within the scope of the present invention. .
  • the degree of mutation is within the acceptable range if the homology with the amino acid sequence shown in SEQ ID NO: 1 (SEQ ID NO: 1) is 80% or more.
  • the antibody (for example, polyclonal antibody or monoclonal antibody) or antiserum of the present invention can be produced by using the protein TIG104 ⁇ or a partial peptide of TIG104 ⁇ as an antigen according to a known method for producing an antibody or antiserum. Can be.
  • the animal may be administered to an animal at a site capable of producing an antibody by administration, or may be administered together with a carrier or diluent.
  • Complete Freund's adjuvant or incomplete Freund's adjuvant may be administered in order to enhance the antibody-producing ability upon administration. Administration is usually performed once every 2 to 6 weeks, for a total of 2 to about 0 times.
  • the warm-blooded animals used include, for example, monkeys, egrets, dogs, guinea pigs, mice, rats, sheep, goats, and chickens.
  • the gene tig104 of the present invention controls the co-reaction of c-Myc, one of the nuclear transcriptional regulators, and is therefore useful for controlling cell proliferation and differentiation. Furthermore, based on the fact that c-myc amplification was observed in various tumors such as human leukemia, lung cancer, and gastric cancer, the application of the gene ti104a and the protein TIG104 ⁇ to cancer therapy,
  • the gene tig104 ⁇ of the present invention is highly expressed in heart and skeletal muscle as described below. Further, considering the physiological significance of the suppression of muscle differentiation by TGF- / 31, the protein TIG104 of the present invention is always in the pre-differentiation stage so that rapid tissue repair can be achieved in the event of muscle tissue damage. It is supposed to have a role in maintaining blast cells in a certain number of episodes. Assuming that TGF- / 31 acts to maintain muscle tissue homeostasis, the protein TIG104, which is a transcript of the target gene tig104, is expressed in heart and skeletal muscle. It is greatly expected to contribute to the development of pharmaceuticals and the like that are supposed to repair tissues.
  • TGF- 31 is known to suppress the onset of myocardial infarction, it will be possible to search for an enhancer of TGF-i31 in suppressing myocardial infarction using the protein TIG104 ⁇ . Conceivable.
  • the present invention will be described in detail with reference to Examples, but it goes without saying that the present invention is not limited to these Examples.
  • MvlLu cells derived from mink lung epithelium were transformed into an Opti-MEM medium (GIBCO-BRL) containing 2% fetal calf serum (NaI gene) and a non-essential amino acid solution (GIBCO-BRL) as a growth medium.
  • the cells were maintained at 37 ° C and 5% C% 2 for subculture.
  • the cells were cultured in a serum-free medium for 24 hours, and then treated with human recombinant TGF-i31 (PEPROTECH) at a final concentration of 1 ng / ml for 1 hour, after two washing steps with the serum-free medium. .
  • TGF-jS1 human recombinant TGF-i31
  • the medium was removed, and total RNA was recovered using RNe asy Min ikit (QIAGEN).
  • total RNA was collected from the control group, TGF-; 81 untreated group.
  • Pol y (A) + RNA was purified. Using 2 mg equivalent of po1y (A) + RNA prepared from each of the TGF- / 31-treated group and the untreated group, using PCR-select cDNA subtraction kit (CLONTECH) Thus, subtraction cDNAs were synthesized and prepared.
  • cDNA fragments were incorporated into pT7BueT-vector (Novagen) and introduced into Escherichia coli DH5a (TOYOBO) to prepare a subtraction library.
  • Colony hybridization was performed using the probe labeled with [32p] as a probe. Subsequent screening was performed on the remaining 790 independent clones excluding clones corresponding to both cDNAs.
  • BLASTSearch was used to examine whether each of the 150 nucleotide sequences obtained was derived from a known gene. As a result, 117 genes were registered in the existing gene database and 33 were unregistered. Of the registered sequences, the function of the gene product was reported for only 92 ore, and only the sequence information was heard for 2 There were five.
  • RNA was prepared from the MvLLu cells treated with TGF-] 31 and the untreated group, and 22 g of each was electrophoresed on a 1% agarose gel, followed by nylon membrane Hy b It was transcribed into ond_N + (Pharmacia—Amersham). After immobilizing RNA on the membrane by the UV cross-linking method, each cDNA labeled with a hybridization solution (7% SDS, 0.5 M phosphate buffer pH 7.4, ImM EDTA) and [ 32 P] The membrane was immersed in the mixed solution with the probe and incubated at 65 ° C for 16 hours. After hybridization, the non-specifically adsorbed probe was removed, and radioactivity specifically remaining on the membrane was detected by autoradiography. As a result, an increase in mRNA after treatment with TGF-1 was confirmed for the two types of genes.
  • the base sequence was determined by PCR using the plasmid as type III.
  • Frymer used W: T 7 promo torpr ime r (Nonagen), DNA sequenc i ng ki U: 3 ⁇ 4B i g Dye te rmi na tor cyc les equenc i ng re ady re ac ti on (PERKIN ELMER), and Gene PCR PCR System
  • the DNA base sequence was determined using Genetic Ana 1yzer (PERKIN ELMER).
  • CTGF binding fiber-derived growth factor
  • the resulting cDNA of the human gene tig104 had a 5 ′ untranslated region of 198 bp, a ⁇ RF of 1068 bp, and a 3 ′ untranslated region of 225 bp.
  • the ORF encodes a protein consisting of 355 amino acid sequences, and its estimated molecular weight was calculated to be 41.6 kDa.
  • Marathon-Ready cDNA purchased from Clonetech, Inc.
  • poly (A) + RNA was prepared, and the expression levels of mRNA were compared by Northern blotting.
  • an antigen was prepared.
  • a human gene, tig104a cDNA (a fragment of 739 to 1068 bp in SEQ ID NO: 1, which encodes a polypeptide consisting of 109 amino acids from the 247th palin residue to the C-terminus) was daltathione-1S transferase (GST)
  • GST daltathione-1S transferase
  • PGEX5X-1 (Pharmacia-AmershamII) was recombined and introduced into the E. coli XL1-B1ue strain. After adding the recombinant E.
  • 0.5 ml of the antigen sample protein concentration: 2 mg Zml
  • TiterMaxGo 1d TiterMaxGo 1d
  • the adjuvant solution was injected subcutaneously and intradermally in four dorsal parts and two places on both sides of the posterior cervix of New Zealand rabbits (purchased from Nippon Biological Materials) in 0.1-0.2 ml units. Three weeks after the first antigen immunization, antigen immunization was performed again, and about 2 weeks later, 20 ml of blood was collected.
  • the serum fraction (about 10 ml) was separated from whole blood by centrifugation, and after adding a saturated ammonium sulfate solution, centrifugation was performed, and the supernatant fraction was collected. Next, the supernatant fraction was passed several times through a force ram filled with daltathione sepharose 4B to which GST protein had been adsorbed, and the passed fraction was used as anti-human TIG104 ⁇ ⁇ heron antiserum.
  • Human guru cells HepG2 were seeded on canopy grass, and the pcDNA3.1 / Myc-human tig104 ⁇ plasmid was introduced. Further, the cover glass to which the cells were attached was removed, washed with PBS, immersed in a cell fixative (phosphate buffer containing 4% formaldehyde), and allowed to stand at room temperature for 15 minutes.
  • a cell fixative phosphate buffer containing 4% formaldehyde
  • buffer 1% TritonX-100, 5 OmMTris-HC1 pH 7.4, 10 OmM NaC 50 mM NaF, ImM DTT, ImMPMSF
  • an anti-FLAG antibody and Protein G Sepharose were added to the cell lysate to perform an immunoprecipitation experiment.
  • the proteins in the gel were transferred to a hydrophobic membrane I mobir on-P (Millipore), and blocking was performed.
  • a detection reaction was performed using an anti-FLAG antibody as a primary antibody and an anti-mouse IgG antibody monoalkaline phosphatase as a dimeric antibody. The results are shown in FIG.
  • the human Myc expression vector and the FLAG-labeled human TI G104 expression vector were simultaneously introduced into human 293 T cells, and after 48 hours, a cell lysate was prepared. Immunoprecipitation experiments were performed using antibody C-33 (Santa Cruz Biotechno 1 ogy) and protein G sepharose. Next, the immunoprecipitate was developed on an SDS-polyacrylamide gel, and the protein in the gel was transferred to Imob iron-P. Then, the FLAG-labeled TIG104 protein was purified using an anti-FLAG antibody and an anti-mouse IgG antibody mono-alkaline phosphatase. Was detected. The results are shown in FIG.
  • HepG2 cells derived from human ff ® have pcDNA3.1 (10) FLAG human
  • HA label is a kind of artificial epitope like FLAG and its amino acid sequence is Y PYDVP DYAI
  • the prepared cell lysate was subjected to immunoprecipitation by adding an anti-human Myc antibody and Protein G Sepharose.
  • the immunoprecipitate was developed on an SDS-polyacrylamide gel and transferred to a hydrophobic membrane-Imobion-P, and then an anti-HA antibody and an anti-mouse IgG antibody-alkaline phosphatase were added.
  • HA-labeled human My c protein was detected by the Western blot method used.
  • the human TIG104 ⁇ mutant used lacked the C-terminal region including F-boX completely and was composed only of the region that interacts with the human Myc protein. It is expected to have an interference effect on the interaction of the human Myc protein.
  • FIG. 1 shows the results of forced expression of recombinant human gene TIG104 in human cell line 293 T cells.
  • Lane 1 pcDNA3.1 (+) FLAG vector was introduced, and immunoprecipitation was performed using an anti-FLAG antibody.
  • Lane 2 p cDNA3.1 (+) FLAGt TIG104K vector was transfected and immunoprecipitated using an anti-FLAG antibody.
  • FIG. 2 shows the results of a liver-liver interaction experiment between human TI G104 protein and human Skp1 protein.
  • Lane 1 1/10 amount of [ 35 S] -labeled human TI G104 Q! Protein used in the binding reaction (indicated by WT; indicated by an arrow), and line 2: 1Z10 used in the binding reaction The amount of [ 35 S] -labeled human TI G104 ⁇ ⁇ mutant (161 taF protein (denoted by delta F; indicated by arrows)), lane 3: GST and [ 35 S] -labeled human TI G104 Q!
  • Protein lanes 4: GST and [35 S] labeled human TI G104 «variant (16 1 ta F protein, lane 5: GST- S kp 1 with [35 S] labeled human Bok TI G104 alpha protein, lane 6: GST — Skpl and [ 35 S] -labeled human TI G104 «mutant de 1 taF protein.
  • FIG. 3 shows the results of a co-precipitation experiment of human TIG104 ⁇ protein and human Myc protein in human cell line 293 T cells.
  • Lane 1 p cDNA3.1 (+) human c—Myc vector was transfected.
  • Lane 2 p cDNA3.1 (+) FLAG human TI G104 ⁇ vector was transfected.
  • Lane 3 p cDNA3.1 (+) human c Myc vector and p CDNA3.1 (+) FLAG human TIG104 vector were transfected simultaneously.
  • Upper panel immunoprecipitation using anti-Myc antibody, and Western blot using anti-FLAG antibody.
  • Middle panel immunoprecipitation with anti-Myc antibody, and Western blot using anti-Myc antibody.
  • Lower panel Western blot using anti-FLAG antibody was performed on each cell lysate before immunoprecipitation.
  • FIG. 4 shows the amino acid sequence of TIG104 ⁇ .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à une protéine comportant la séquence d'acides aminés représentée par SEQ ID NO:1, ou à un facteur de régulation de la protéolyse du type protéasome, qui comprend une séquence d'acides aminés dérivée de la séquence d'acides aminés représentée par SEQ ID NO:1 par délétion, substitution ou addition d'un ou de plusieurs acides aminés. L'invention se rapporte à un ADN comportant la séquence de base représentée par SEQ ID NO:2 ou à un ADN susceptible d'être hybridé avec l'ADN de SEQ ID NO:2 dans des conditions rigoureuses et codant pour un facteur de régulation de la protéolyse du type protéasome.
PCT/JP2001/000689 2000-02-01 2001-02-01 NOUVEAU GENE TIG104α ET PROTEINE TIG104α CODEE PAR CE GENE WO2001057203A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001230560A AU2001230560A1 (en) 2000-02-01 2001-02-01 Novel gene tig104alpha and protein tig104alpha encoded thereby

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-23533 2000-02-01
JP2000023533 2000-02-01

Publications (1)

Publication Number Publication Date
WO2001057203A1 true WO2001057203A1 (fr) 2001-08-09

Family

ID=18549679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/000689 WO2001057203A1 (fr) 2000-02-01 2001-02-01 NOUVEAU GENE TIG104α ET PROTEINE TIG104α CODEE PAR CE GENE

Country Status (2)

Country Link
AU (1) AU2001230560A1 (fr)
WO (1) WO2001057203A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1425289A2 (fr) * 2001-01-30 2004-06-09 Regeneron Pharmaceuticals, Inc. Nouvelles molecules d'acide nucleique et polypeptidiques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012679A1 (fr) * 1998-08-28 2000-03-09 New York University Nouvelles ubiquitine ligases utiles comme cibles therapeutiques
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
WO2000070047A2 (fr) * 1999-05-14 2000-11-23 Incyte Genomics, Inc. Molecules completes exprimees dans des tissus humains

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012679A1 (fr) * 1998-08-28 2000-03-09 New York University Nouvelles ubiquitine ligases utiles comme cibles therapeutiques
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
WO2000070047A2 (fr) * 1999-05-14 2000-11-23 Incyte Genomics, Inc. Molecules completes exprimees dans des tissus humains

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LADEANA HILLIER ET AL.: "Generation and analysis of 280,000 human expressed sequence tags", GENOM. RES., vol. 6, no. 9, 1996, pages 807 - 828, XP002942261 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1425289A2 (fr) * 2001-01-30 2004-06-09 Regeneron Pharmaceuticals, Inc. Nouvelles molecules d'acide nucleique et polypeptidiques
EP1425289A4 (fr) * 2001-01-30 2004-10-13 Regeneron Pharma Nouvelles molecules d'acide nucleique et polypeptidiques

Also Published As

Publication number Publication date
AU2001230560A1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
JP3294575B2 (ja) Ｉｇｆ−１レセプターと相互作用するタンパク質、それをコードする遺伝子及びそれらの使用
JP2000078991A (ja) ヒト・ナトリウム依存性リン酸輸送体（ｉｐｔ―１）
JPH08509118A (ja) Ｍａｘとの相互作用蛋白質並びに関連分子および方法
JP2000093186A (ja) Ｆｒｉｚｚｌｅｄ―４ポリペプチドおよびＦｒｉｚｚｌｅｄ―４ポリヌクレオチド
US6716964B1 (en) CtIP, a novel protein that interacts with CtBP and uses therefor
AU746135B2 (en) PARG, a GTPase activating protein which interacts with PTPL1
JP4190291B2 (ja) 癌細胞の増殖を調節するのに有用なポリヌクレオチド
WO2001057203A1 (fr) NOUVEAU GENE TIG104α ET PROTEINE TIG104α CODEE PAR CE GENE
JP2003210183A (ja) ヒトＩκＢ−β
WO2000056756A2 (fr) Proteine de liaison de l'element regulateur de prolactine et son utilisation
JPH10304883A (ja) 新規化合物
EP0881294A2 (fr) HOEFCC11, variante d'épissure de HAS2
JP2001057888A (ja) 大腸癌抑制遺伝子関連蛋白質
US6696547B2 (en) Mutant DEDD proteins for regulating apoptosis
JP2000060575A (ja) Ｗｎｔ―６ポリペプチドおよびＷｎｔ―６ポリヌクレオチド
US20020146728A1 (en) IGF-1 receptor interacting proteins
CA2593541A1 (fr) Identification de la phospholipase a2 comme cible dans le traitement du cancer, specialement le cancer colorectal et le mecanisme d'action de celui-ci
JPH11113580A (ja) 新規化合物
JP2002191377A (ja) ヒト・ペロタ相同体
US6768003B1 (en) Nucleic acids that encode transcriptional adaptor proteins
WO2001038531A1 (fr) Nucleoproteine humaine possedant un domaine www et polynucleotide codant cette nucleoproteine
JP2002000274A (ja) 新規遺伝子及びそれにコードされる蛋白質
JPH10168098A (ja) 腫瘍リンパ節転移関連抗原エピトープ
JP2000500962A (ja) Ｆｍｒ１関連蛋白質
EP1385957A1 (fr) Fonctions pour les polypeptides et les acides nucleiques d52 et ra006

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 558018

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase